Company news
Compugen Ltd. news in 2025
Compugen Ltd.'s news releases, calls and decks from 2025, newest first.
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
December 16, 2025
Compugen Reports Third Quarter 2025 Results
November 9, 2025
Compugen to Participate in Stifel 2025 Healthcare Conference
November 3, 2025
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
October 26, 2025
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
October 12, 2025
Compugen to Present at SITC 2025
October 5, 2025
Compugen to Present Research at the Single Cell Genomics 2025 Conference
September 7, 2025
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 27, 2025
Compugen Reports Second Quarter 2025 Results
August 5, 2025
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
July 27, 2025
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
July 22, 2025
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
July 20, 2025
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
June 11, 2025
Compugen Reports First Quarter 2025 Results
May 18, 2025
Compugen Announces Leadership Transitions Effective September 2025
May 12, 2025
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025
May 4, 2025
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
March 25, 2025
Correction: Compugen Ltd.
March 3, 2025
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
March 2, 2025
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
February 25, 2025
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
February 17, 2025
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 3, 2025
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
January 7, 2025